AOD-9604 research guide for Lot. HGH fragment studied for fat metabolism — covers mechanism, purity standards, COA verification, and how to source AOD-9604.
Most researchers trying to source AOD-9604 in Lot immediately realize that local retail options are virtually absent. What this means for Lot researchers is that your location matters far less than your ability to verify analytical documentation — and those verification methods are accessible to anyone. Vendors worth sourcing from proactively publish batch-matched Certificates of Analysis showing HPLC purity data, mass spec identity confirmation, endotoxin levels, and residual solvent results — all for the specific lot you are purchasing. Use this guide to evaluate AOD-9604 vendors rigorously — the quality evaluation approach outlined here apply whether you are in Lot or anywhere else.
The Science Behind AOD-9604
CJC-1295 with DAC (Drug Affinity Complex) is a GHRH analogue with an extended half-life achieved through DAC technology that enables covalent binding to albumin. This modification extends the half-life from minutes (for native GHRH) to approximately 6-8 days, creating a sustained elevation in basal GH levels rather than the pulsatile pattern produced by GHRP compounds. This pharmacokinetic distinction is significant for research design: AOD-9604 based on CJC-1295 with DAC produces a different GH secretion pattern than GHRP compounds, with different downstream effects on IGF-1 and protein synthesis. Researchers in Lot comparing compounds in this class should account for these pharmacokinetic differences in their experimental design.
AOD-9604 Purchasing Guide
Before looking at individual vendors, understand what genuine quality documentation contains — so you can identify whether a supplier meets the standard. When reviewing a AOD-9604 COA, verify: the batch number matches your product, HPLC purity is ≥98%, mass spec establishes identity, and endotoxin levels are at acceptable levels for the intended application. Negative indicators in AOD-9604 vendor evaluation: prices far under typical market pricing, no information about manufacturing source, no community presence, and COAs that do not include endotoxin results. Bacteriostatic water is the appropriate reconstitution medium for AOD-9604 — it contains 0.9% benzyl alcohol that suppresses bacterial proliferation and extends reconstituted shelf life to 4 weeks when kept refrigerated.
Order AOD-9604 — ships to Lot
COA-verified · International tracking · Research grade
All use of AOD-9604 in Lot or anywhere is research use only — this compound is not approved for clinical human use, and all handling should follow research laboratory protocols. Lyophilised AOD-9604 should be frozen at −20°C as soon as it arrives; avoid repeatedly thawing and refreezing reconstituted peptide by dividing into single-dose aliquots before freezing. Bacterial endotoxin contamination is the most serious safety risk specific to research peptides — verify endotoxin testing is included in the batch-specific COA before any injectable research application. For any individual considering AOD-9604 outside a formal research context: seek medical advice first — this compound is not a licensed human medication and its known risks are not comparable to approved pharmaceuticals.
Frequently Asked Questions
How does AOD-9604 differ from growth hormone?
AOD-9604 contains only the fat-metabolism-relevant fragment of growth hormone (the C-terminal region) without the IGF-1-stimulating N-terminal domain. This means it targets fat cells' beta-adrenergic receptors for lipolytic effects without producing the anabolic IGF-1 signaling associated with full-length GH.
What is the clinical trial history of AOD-9604?
AOD-9604 has undergone multiple Phase II clinical trials for obesity treatment by Metabolic Pharmaceuticals in Australia. The trials showed safety and tolerability but mixed efficacy results for weight loss. It holds GRAS (Generally Recognized As Safe) status from the FDA for food use, which is unusual for research peptides.
What is AOD-9604?
AOD-9604 is a synthetic peptide analogue of the C-terminal fragment of human growth hormone (amino acids 177-191), with an additional tyrosine residue at the N-terminus. It has been studied for fat metabolism effects, specifically lipolysis stimulation and lipogenesis inhibition, without the IGF-1-stimulating effects of full-length GH. It has undergone clinical trials for obesity treatment.